Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Inflazyme Pharmaceuticals (T.IZP) -- Ignore unavailable to you. Want to Upgrade?

To: Harold Lehman who wrote (954)	5/28/1998 11:57:00 PM
From: Jeremy Niles Harris	Respond to of 1501

My major concern with the company is their failure to aggressively pursue the TB testing. Anytime that I have called the company virtually no useful information is given. Surely someone must talk to Cortecs to get a timetable and to find out if they have encountered any problems. After all they are both supposed to benefit economically from this project.

To: Harold Lehman who wrote (954)	5/31/1998 4:21:00 PM
From: Sean Janzen	Respond to of 1501

Harold, Thanks for taking the effort inform investors on what is happening at IZP. I spoke with Michael Ligget a few weeks ago. He mentioned that Oona Davis was no longer with the company and that there were no immediate plans to fill her position. That tells me we can be fairly certain the company will have no news to release in the near term. The recent developments at Signal, Tularik and Icos, are very exciting. ICOS closed on Friday at US$21 1/16+ up over US$4 13/16 on 23+ million shares traded and up over US$13. from US$7 5/8 in the last year As we all know IZP has a great deal of potential. Lets see if they can deliver. We should see some significant price movement, either up or down, within the next year.

To: Harold Lehman who wrote (954)	6/1/1998 7:28:00 PM
From: Sean Janzen	Read Replies (1) \| Respond to of 1501

Any comments on this news? CONTACT: Mr. Michael Liggett Chief Financial Officer (800) 315-3660, (604) 279-8511 $6 MILLION PRIVATE PLACEMENT Vancouver, B.C., June 1, 1998 ----------Inflazyme Pharmaceuticals Ltd. (VSE:IZP; OTC-BB:IZYPF) is pleased to announce that it has arranged the private placement of 7,017,544 Units at $0.855 per Unit, for total proceeds of $6,000,000. Each Unit consists of one common share and one-fifth of one common share purchase warrant. One whole warrant will provide a holder with the right to purchase one common share of the company at a purchase price of $1.14 for a period of three and one-half years. The private placement agreement is subject to the completion of documentation, due diligence and approval by the Vancouver Stock Exchange. The net proceeds will be used to fund ongoing research and development and for general corporate purposes. There is no finders fee payable in connection with this private placement. Inflazyme Pharmaceuticals Ltd. is an emerging biopharmaceutical company focused on the discovery and development of drugs that act through the regulation of gene expression and biochemical pathways involved in inflammatory diseases. The statements made in this press release may contain certain forward-looking comments. Actual events may differ from the Company's expectations. In addition to the matters described in the press release, future actions by the U.S. Food and Drug Administration or equivalent regulatory authorities in various countries, results of pending or future clinical trials, as well as risk factors from time to time in the Company's SEC reports, may affect the actual results achieved by the Company. Exemption from registration pursuant to Rule 12g3-2(b), Reg. No. 82-2317. The Vancouver Stock Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.